Mural Oncology Plc (MURA)

Apr 10, 2025

Spin-Off Research Slashes Mural Oncology Valuation - Forbes

Apr 10, 2025

Apr 08, 2025

Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech

Apr 08, 2025

Apr 07, 2025

BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer - Curetoday

Apr 07, 2025

Mar 31, 2025

40,025 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Virtu Financial LLC - Defense World

Mar 31, 2025

Mar 29, 2025

HC Wainwright Comments on Mural Oncology Q1 Earnings - Defense World

Mar 29, 2025

Mar 28, 2025

Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects - Seeking Alpha

Mar 28, 2025

Mar 28, 2025

HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00 - Defense World

Mar 28, 2025

Mar 27, 2025

Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals

Mar 27, 2025

Mar 26, 2025

Mural Oncology stock target cut to $6 at H.C. Wainwright By Investing.com - Investing.com UK

Mar 26, 2025

Mar 26, 2025

Mural Oncology downgraded to Hold from Buy at JonesResearch - TipRanks

Mar 26, 2025

Mar 26, 2025

Raymond James downgrades Mural Oncology after ovarian cancer failure - TipRanks

Mar 26, 2025

Mar 26, 2025

Mural Oncology (NASDAQ:MURA) Downgraded by Raymond James to Outperform - Defense World

Mar 26, 2025

Mar 26, 2025

Mural Oncology (NASDAQ:MURA) Given Hold Rating at Jones Trading - Defense World

Mar 26, 2025

Mar 26, 2025

Mural Oncology (NASDAQ:MURA) Downgraded to “Equal Weight” Rating by Morgan Stanley - Defense World

Mar 26, 2025

Mar 25, 2025

Raymond James cuts Mural Oncology stock rating, slashes target to $6 - Investing.com UK

Mar 25, 2025

Mar 25, 2025

Morgan Stanley cuts Mural Oncology stock rating to Equal-weight By Investing.com - Investing.com UK

Mar 25, 2025

Mar 25, 2025

Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57% - Clinical Trials Arena

Mar 25, 2025

Mar 25, 2025

Mural Oncology downgraded to Equal Weight from Overweight at Morgan Stanley - TipRanks

Mar 25, 2025

Mar 25, 2025

Mural Oncology halts ovarian cancer drug development By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Mural Oncology sinks on nemvaleukin miss in ovarian cancer - BioWorld MedTech

Mar 25, 2025

Mar 25, 2025

Mural Oncology halts ovarian cancer trial By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga

Mar 25, 2025

Mar 25, 2025

Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha

Mar 25, 2025

Mar 25, 2025

Jones Trading cuts Mural Oncology stock rating to hold By Investing.com - Investing.com UK

Mar 25, 2025

Mar 25, 2025

Mural Oncology halts ovarian cancer trial - Investing.com India

Mar 25, 2025

Mar 25, 2025

Mural Oncology halts ovarian cancer drug development - Investing.com India

Mar 25, 2025

Mar 25, 2025

Mural Oncology to Stop Development of Nemvaleukin for Ovarian Cancer; Shares Sink Pre-Bell - MarketScreener

Mar 25, 2025

Mar 25, 2025

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer - The Manila Times

Mar 25, 2025

Mar 25, 2025

Clinical Trial Setback: Mural's Cancer Drug Falls Short in Phase 3 Ovarian Cancer Study - Stock Titan

Mar 25, 2025

Mar 18, 2025

Acquisition Of MSC Lung Cancer Screening Test Sends Shares Of This Micro Cap Higher - The Globe and Mail

Mar 18, 2025

Mar 18, 2025

Mural Oncology (MURA) Expected to Announce Earnings on Tuesday - Defense World

Mar 18, 2025

Mar 17, 2025

Q1 EPS Estimates for Mural Oncology Reduced by HC Wainwright - Defense World

Mar 17, 2025

Mar 14, 2025

HC Wainwright Reiterates Buy Rating for Mural Oncology (NASDAQ:MURA) - Defense World

Mar 14, 2025

Mar 12, 2025

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times

Mar 12, 2025

Mar 11, 2025

Mural Oncology enters agreement for share sales By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 11, 2025

Mural Oncology enters agreement for share sales - Investing.com

Mar 11, 2025

Mar 11, 2025

Mural Oncology Slashes Losses by 42% as Two Major Cancer Trial Results Approach - StockTitan

Mar 11, 2025

Mar 05, 2025

Mural Oncology CEO Caroline Loew sells shares worth $14,491 - Investing.com

Mar 05, 2025

Mar 05, 2025

Mural oncology officer sells shares worth $9,308 - Investing.com India

Mar 05, 2025

Mar 05, 2025

Mural oncology officer sells shares worth $9,308 By Investing.com - Investing.com South Africa

Mar 05, 2025

Feb 25, 2025

Mural Oncology's chief medical officer sells $51,293 in shares - Investing.com India

Feb 25, 2025

Feb 25, 2025

Mural Oncology’s chief medical officer sells $51,293 in shares - Investing.com

Feb 25, 2025

Feb 18, 2025

Exclusive: Mural Oncology Unveils Next-Gen Cancer Treatment Strategy at Major Healthcare Conference - StockTitan

Feb 18, 2025

Feb 18, 2025

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 18, 2025

Feb 17, 2025

Mural Oncology plc (NASDAQ:MURA) Short Interest Update - MarketBeat

Feb 17, 2025

Feb 12, 2025

Alkermes plc (ALKS) reports earnings - Quartz

Feb 12, 2025

Feb 11, 2025

We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully - Yahoo Finance

Feb 11, 2025

Feb 10, 2025

Mural Oncology (NASDAQ:MURA) Trading 8.8% HigherHere's What Happened - MarketBeat

Feb 10, 2025

Feb 07, 2025

Mural Oncology (NASDAQ:MURA) Trading 8.8% Higher – Here’s Why - Defense World

Feb 07, 2025

Jan 27, 2025

Jones Trading sets $16 target on Mural Oncology stock By Investing.com - Investing.com Nigeria

Jan 27, 2025

Jan 27, 2025

This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jan 27, 2025